-
公开(公告)号：EP2952510A4
公开(公告)日：2017-02-15
申请号：EP14746385
申请日：2014-01-27
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , CENTAURUS BIOPHARMA CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： XIAO DENGMING , XU XINHE , LIU XIJIE , HU YUANDONG , YU HONGHAO , LIU ZHIHUA , PENG YONG , SUN YINGHUI , LUO HONG , KONG FANSHENG , HAN YONGXIN , SUN JIAN
IPC分类号： C07D401/04 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61P35/00 , C07D213/73 , C07D213/74 , C07D401/06 , C07D401/14 , C07F9/6558
CPC分类号： C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/675 , C07D213/73 , C07D213/74 , C07D401/04 , C07D401/06 , C07F9/65583
摘要： Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.
摘要翻译： 公开了具有蛋白激酶抑制活性的2-氨基吡啶衍生物，其制备方法和药物组合物。还公开了化合物及其药物组合物在制备用于治疗和/或预防蛋白激酶相关疾病的药物中的用途。
-
公开(公告)号：EP3176160A4
公开(公告)日：2017-12-06
申请号：EP15826817
申请日：2015-07-31
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD , CENTAURUS BIOPHARMA CO LTD
发明人： GONG FENG , LI XINLU , ZHAO RUI , ZHANG XIQUAN , XU XINHE , LIU XIJIE , XIAO DENGMING , HAN YONGXIN
IPC分类号： C07D401/14 , A61K31/444 , A61K31/496 , A61P35/00 , C07D213/73
CPC分类号： C07D401/14 , A61K31/444 , A61K31/496 , C07D213/73
摘要： The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.
-
公开(公告)号：EP3235819A4
公开(公告)日：2017-11-01
申请号：EP15869312
申请日：2015-12-15
申请人： CENTAURUS BIOPHARMA CO LTD , CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： ZHU LI , XIAO DENGMING , HU YUANDONG , DAI LIGUANG , DUAN XIAOWEI , SUN YINGHUI , PENG YONG , KONG FANSHENG , LUO HONG , HAN YONGXIN , YANG LING , WANG SHANCHUN
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/519 , A61K31/5377 , C07D487/04
摘要： The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
-
公开(公告)号：EP3050880A4
公开(公告)日：2017-04-26
申请号：EP14849754
申请日：2014-09-28
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , CENTAURUS BIOPHARMA CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： XIAO DENGMING , ZHU YAN , HU YUANDONG , WANG HUTING , LI JIJUN , PENG YONG , ZHANG HUI , LUO HONG , KONG FANSHENG , HAN YONGXIN
IPC分类号： C07D401/12 , A61K31/517 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/12 , C07D405/14
CPC分类号： C07D403/12 , C07D401/12 , C07D401/14 , C07D405/14
摘要： The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo.
摘要翻译： 本发明涉及式（I）所示的喹唑啉衍生物及其制备方法，含有式（I）所示化合物的药物组合物，以及该化合物在制备治疗和预防肿瘤药物中的应用。 本发明化合物可以不可逆地阻止EGFR的磷酸化，有效抑制癌细胞的信号传导，因此具有较高的体外和体内抗肿瘤活性。
-
公开(公告)号：EP2635587A4
公开(公告)日：2014-03-19
申请号：EP11837567
申请日：2011-11-01
发明人： XIAO DENGMING , ZHU LI , HU YUANDONG , WANG SHIXIN , YU RONG , HU WEI , LIANG ZHI , LIU XIJIE , HU QUAN
IPC分类号： C07D491/048 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4545 , A61K31/5377 , A61P29/00 , A61P35/00 , C07D495/04 , C07D498/04 , C07D513/04
CPC分类号： C07D513/04 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4545 , A61K31/5377 , C07D491/048 , C07D495/04 , C07D498/04
-
6.发明公开
公开(公告)号：EP3257857A4
公开(公告)日：2018-08-01
申请号：EP16748717
申请日：2016-02-04
申请人： CENTAURUS BIOPHARMA CO LTD , CHAI TAI TIANQING PHARMACEUTICAL GROUP CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： XU XINHE , SHEN YU , XIAO DENGMING , LUO HONG , PENG YONG , HAN YONGXIN , ZHANG AIMING , YANG LING
IPC分类号： C07D513/14 , A61K31/4035 , A61K31/407 , A61K31/4162 , A61K31/542 , A61P3/10 , A61P5/50 , C07D405/04 , C07D487/04 , C07D495/04
CPC分类号： C07D513/14 , A61K31/4035 , A61K31/407 , A61K31/4162 , A61K31/542 , A61P1/00 , A61P3/04 , A61P7/00 , A61P25/00 , C07D405/04 , C07D487/04 , C07D495/04
摘要： The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition.
-
公开(公告)号：EP2670746A4
公开(公告)日：2014-07-30
申请号：EP12742266
申请日：2012-01-31
发明人： XIAO DENGMING , ZHU YAN , HU YUANDONG , WANG HUTING , LIU YULIANG , LI JIJUN , SUN DEGUANG , WANG ZHE , WEI YONGHENG , WANG ZANPING , TANG GUOJING , JING LUTAO
IPC分类号： C07D401/12 , A61K31/4523 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P43/00 , C07D401/14 , C07D451/14
CPC分类号： C07D401/04 , C07D401/12 , C07D401/14 , C07D413/14 , C07D451/14 , C07D471/04
-
8.发明公开NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS 审中-公开中华神经病学杂志（DEREN VERWENDUNG ALS SELEKTIVEÖSTROGENREZEPTORMODULATOREN）
公开(公告)号：EP2797889A4
公开(公告)日：2015-06-03
申请号：EP12863580
申请日：2012-12-28
发明人： XIAO DENGMING , ZHU LI , HU YUANDONG , YU RONG , HU WEI , ZHAO NA , PENG YONG , LUO HONG , HAN YONGXIN
IPC分类号： C07D213/61 , C07C217/20 , C07C255/54 , C07D207/08 , C07D207/12 , C07D213/38 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/74 , C07D231/56 , C07D235/06 , C07D239/34 , C07D263/56 , C07D285/14 , C07D295/096 , C07D307/79 , C07D307/82 , C07D333/16 , C07D333/28 , C07D401/12
CPC分类号： C07C217/18 , C07C215/48 , C07C217/20 , C07C255/54 , C07C2601/14 , C07D207/09 , C07D207/12 , C07D213/38 , C07D213/61 , C07D213/63 , C07D213/64 , C07D213/74 , C07D231/56 , C07D239/34 , C07D285/10 , C07D307/81 , C07D307/82 , C07D333/20 , C07D333/28 , C07D405/06 , C07D405/12
-
9.发明公开2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS 审中-公开2,4-二氨基-6,7-二氢-5H-吡咯并[2,3-b]嘧啶衍生物ALS FAK / PYK2-HEMMER
公开(公告)号：EP2661437A4
公开(公告)日：2014-07-02
申请号：EP12732345
申请日：2012-01-07
发明人： XIAO DENGMING , CHENG LIANG , LIU XIJIE , HU YUANDONG , XU XINHE , LIU ZHIHUA , ZHANG LIPENG , WU WEI , WANG SHULONG , SHEN YU , LI GEN , WANG YIN , ZHAO SHENG , LI CHONGLONG , TANG JIA , YU HONGHAO
IPC分类号： C07D487/04 , A61K31/505 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02
CPC分类号： C07D487/04 , A61K31/4523 , A61K31/519 , A61K31/5377 , A61K31/541 , C07D401/12 , C07D413/12 , C07D417/12 , C07D493/12
摘要： The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.
摘要翻译： 本发明涉及一种新型的作为FAK和/或Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物，其制备方法和组合物 以及该化合物用于抑制FAK和/或Pyk2的方法和用于治疗FAK和/或Pyk2介导的病症或疾病的方法。
-
公开(公告)号：EP3141546A4
公开(公告)日：2018-01-10
申请号：EP15789528
申请日：2015-05-07
发明人： HAN YONGXIN , ZHU LI , XIAO DENGMING , PENG YONG , LUO HONG
IPC分类号： C07D401/04 , A61K31/415 , A61K31/454 , A61K31/5377 , A61P11/06 , A61P19/02 , A61P19/04 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , C07D231/38 , C07D403/04
CPC分类号： C07D401/04 , A61K31/415 , A61K31/454 , A61K31/5377 , C07D231/38 , C07D403/04
摘要： Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.018 秒)
